Alleviation of neuropathic pain by trazodone in rats

Rajalakshimi Vasudevan*, Geetha Kandasamy2, Dalia Almaghaslah2, Mona Almanasef2, Ali Alqahatani1, Afaf Aldahish1, Krishnaraju Venkatesan1, Premalatha Paulsamy3, Maheswari C4, Shadma Wahab5

1Department of Pharmacology, College of Pharmacy, King Khalid University, Abha, Kingdom of Saudi Arabia, 2Department of Clinical Pharmacy, College of Pharmacy, King Khalid University, Abha, Kingdom of Saudi Arabia, 3College of Nursing, King Khalid University, Saudi Arabia, 4Department of Clinical Pharmacy, College of Pharmacy, Shaqra University, Kingdom of Saudi Arabia, 5Department of Pharmacognosy, College of Pharmacy, King Khalid University, Kingdom of Saudi Arabia

Neuropathic pain is generally characterised by an abnormal sensation (dysesthesia), an increased response to painful stimuli (hyperalgesia), and pain in response to a stimulus that does not normally provoke pain (alldynia). The present study was designed to investigate the effect of trazodone (5mg/kg and 10mg/kg) on peripheral neuropathic pain induced by partial sciatic nerve ligation in rats. Mechanical hyperalgesia, cold allodynia and thermal hyperalgesia were assessed by performing the pinprick, acetone, and hot plate tests, respectively. Biochemically, lipid peroxidation level and total calcium levels were measured. However, trazodone administration (5 and 10 mg/kg i.p.) for 21days significantly diminished partial sciatic nerve ligation-induced neuropathic pain along with a reduction in oxidative stress and calcium levels. The results of the present study suggest that trazodone is effective in attenuating partial sciatic nerve ligation-induced painful neuropathic states, which may be attributed to decreased oxidative stress and calcium levels.

Keywords: Hyperalgesia. Cold allodynia. Partial sciatic nerve ligation. Trazodone.

FUNDING INFORMATION: The authors are grateful to the Deanship of Scientific Research, King Khalid University, for sponsoring this study through the large research Group, project under grant number RGP2/186/42 awarded to Krishnaraju Venkatesan.

ACKNOWLEDGMENTS: The authors thank the Deanship of Scientific research at King Khalid University for providing us the adequate support.

INTRODUCTION

Neuropathic pain is usually chronic and caused by damage or disease affecting the somatosensory system. Neuropathic pain may be associated with abnormal sensations called dysesthesias (pain that occurs spontaneously), alldynia (pain as a result of stimulus that does not normally provoke pain) or hyperalgesia (an increased response to a stimulus that is normally painful). In this complex syndrome, some maladaptive variations are found in the entire nociceptive pathway within the central nervous system.

Neuropathic pain (Treede et al., 2008) may result from disorders of the peripheral nervous system or the central nervous system (brain and spinal cord). Up to 7-8% of the global human population is affected, and it may be severe in 5% of affected persons. Neuropathic pain represents the eighth most frequent diagnosis in neurology units, with a prevalence of 3.88% (95% CI: 3.54%-4.22%). The prevalence of neuropathic pain was 2.92% in primary care centres and 6.09% in hospital units. The daily incidence of new neuropathic pain cases was 1.24% (95% CI: 1.05%-1.53%); 1.14% in primary care neurology centres and 1.45% in hospital units. Neuropathic pain is reported to be common...
based on studies from specialty centres and survey studies. The estimated community prevalence of neuropathic pain based on clinical examination (gold standard) was 9.8%. Only the prevalence rate based on self-reporting of nerve pain was higher (12.4%; Montero et al., 2005).

Although neuropathic pain could be acute or chronic in nature, most affected patients suffer from persistent pain comprised of different disease-specific symptoms, each of which having different diagnostic characterisations. Subsequently, it remains difficult to accurately approximate the occurrence and frequency of neuropathic pain (Yawn et al., 2009). As such, the burden of neuropathic pain on patients and healthcare systems is potentially massive. Patients with neuropathic pain experience a poor health-related quality of life and consume a high level of healthcare resources and funding. Future prioritisation for neuropathic pain treatment funding by healthcare policymakers requires further data to clarify its epidemiology, the burden on the health of patients, and the demand on healthcare budgets (Ceyhan et al., 2005). In order to identify novel therapeutics for neuropathic pain and to specifically design compounds for clinical use in treatment models, it is important to recognise newer efficient drugs.

Commonly used anti-depressant drugs such as duloxetine, venlafaxine, and milnacipran, as well as tricyclic antidepressants such as nortriptyline and desipramine improve neuropathic pain either by the reinforcement of descending inhibitory pathways involving serotonergic and noradrenergic projection neurons, by inhibiting the re-uptake of 5-HT and noradrenaline and increasing their availability in the spinal cord, or by either direct or indirect involvement of the opioid system (Bridges et al., 2001). Since relatively little data exists regarding trazodone efficacy in treating neuropathic pain, the present study aims to evaluate the effect of trazodone on the prevention of neuropathic pain induced by sciatic nerve ligation in rats.

**METHODOLOGY**

**Experimental animals**

Male albino rats of the Wistar strain (weighing 150-200 g) were obtained for the present study from the animal house stock of the Department of Pharmacology. All animals were housed at ambient temperature (22±1°C), relative humidity 55±5%, and 12-12 h light/dark cycle. Animals were allowed free access to standard chow diet and water given ad libitum. The study was approved by the Institutional Animal Ethical Committee.

**Procurement of drugs**

Trazodone (50mg) is marketed for the treatment of major depression by the pharmaceutical company Intas under the trade name Trazonil. All the other chemicals such as sodium dodecyl sulphate, acetic acid, thiobarbituric acid, butanol, pyridine, acetone, eosin, and haematoxyline dye were obtained from the local store and were of analytical grade.

**Induction of neuropathic pain by partial sciatic nerveligation method**

Neuropathic pain was induced in rats by partial sciatic nerve ligation (PSL) method using Seltzer’s model. Rats were first anaesthetised with sodium pentobarbitone (60mg/kg i.p.). When the animal lost consciousness, the left sciatic nerve was exposed at mid-thigh level through a small incision and 1/3 to 1/2 of the nerve thickness was tightly ligated with a 7.0 silk suture. The wound was also closed with a single muscle suture and skin clips and then dusted with Aueromycin antibiotic powder (Angela et al., 2016; Seltzer et al., 1990).

**Experimental protocol**

Group I (normal control): Rats (n=6) were not subjected to any surgical procedure and were kept for 3 weeks. Behavioural tests were performed on different days, i.e., day 7, 14 and 21. Thereafter, all animals were sacrificed and subjected to biochemical analysis for the estimation of malanodialdehyde (MDA) levels and total calcium in sciatic nerve tissue.

Group II (PSL): Rats (n=6) were subjected to a surgical procedure to expose and create four loose ligations to the sciatic nerve. The behavioural tests and
the biochemical parameters were assessed as per the method described for Group I.

Group III (trazodone 5mg/kg + PSL): Trazodone (5mg/kg) was administered for 21 days (starting from day 1) in rats (n=6) subjected to PSL. The behavioural tests and biochemical parameters were assessed as per the method described for Group I.

Group IV (trazodone 10mg/kg + PSL): trazodone (10mg/kg) was administered for 21 days (starting from day 1) in rats (n=6) subjected to PSL. The behavioural tests and biochemical parameters were assessed as per the method described for Group I.

Group V (Fluoxetine 10mg/kg + PSL): Fluoxetine (10 mg/kg) was administered for 21 days (Starting from day 1) in rats (n=6) subjected to PSL. The behavioural tests and biochemical parameters were assessed as per the method described for Group I.

Mechanical hyperalgesia

Mechanical hyperalgesia was assessed by the pinprick test (Deuis et al., 2017). The surface of the injured hind paw was touched with the point of abstent gauge needle (at 90° to the syringe) at an intensity sufficient to produce a reflex withdrawal response in normal non-operated animals but insufficient to penetrate the skin. The duration of paw withdrawal was recorded in seconds with a stopwatch. A cut-off time of 20 s was maintained.

Biochemical estimation

Estimation of malanodialdehyde

MDA levels were estimated using 300 μl of 10% trichloroacetic acid added to 150 μl of each sample and centrifuged at 1000 rpm for 10min at 4 °C (Yeon et al., 2005; Meenaet al., 2011). A total of 300 μl of the supernatant were transferred to a test tube and incubated with 300 μl of 0.67% thiobarbituric acid at 100 °C for 25 min. The mixture was allowed to cool on water for 5 min. The resulting pink-stained TBARS were determined using a spectrophotometer at 535 nm.

Estimation of total calcium

Total calcium levels were estimated in the sciatic nerve using sciatic nerve homogenate mixed with 1 ml of trichloroacetic acid (4%) in ice-cold conditions and centrifuged at 2000 rpm for 10 minutes. The clear supernatant was used to estimate total calcium ion by atomic emission spectroscopy at 556 nm.

Statistical analysis:

All values were expressed as mean ±S.E.M. All data were analysed using one-way analysis of variance (ANOVA) followed by Dunnett’s T-test.
RESULTS

Effect of trazodone on thermal hyperalgesia in partial sciatic nerve ligated rats

In the present study, PSL resulted in a significant ($p<0.05$) development of thermal hyperalgesia (jumping or licking time latency) noted by a decrease in left hind paw withdrawal threshold compared to the sham group as shown in the figure 1. Administration of trazodone (5 and 10 mg/kg, i.p.) attenuated a PSL-induced decrease in the nociceptive threshold for thermal hyperalgesia, which was less effective compared to the standard.

![Figure 1](image1.png)

**FIGURE 1** - Effect of trazodone on thermal hyperalgesia in partial sciatic nerve ligated rats.

Effect of trazodone on mechanical hyperalgesia in partial sciatic nerve ligated rats

PSL was associated with the development of mechanical hyperalgesia, as reflected by an increase in hind paw withdrawal duration when compared to the sham group. (Figure 2) Treatment with trazodone (5 and 10 mg/kg i.p.) attenuated the PSL-induced increase in withdrawal duration of the hind paw in response to noxious mechanical stimuli less effectively when compared to the standard drug.

![Figure 2](image2.png)

**FIGURE 2** - Effect of trazodone on mechanical hyperalgesia in partial sciatic nerve ligated rats.
Effect of trazodone on cold allodynia in partial sciatic nerve ligated rats

PSL resulted in a significant ($p<0.05$) development of cold allodynia, as reflected by an increase in the duration of hind paw withdrawal when compared to the sham group. Treatment with trazodone (5 and 10mg/kg i.p.) significantly attenuated the PSL-induced increase in the withdrawal duration of the hind paw in response to non-noxious cold stimuli as shown in the figure 3.

![Figure 3 - Effect of trazodone on cold allodynia in partial sciatic nerve ligated rats.](image)

Effect of trazodone on histopathological changes

The PSL method exhibited significant histopathological changes in the transverse section of neuropathic pain induced groups, including nerve derangement, axonal swelling and an increase in the number of Schwann and satellite cells. Administration of trazodone (5mg/kg and 10mg/kg i.p.) significantly attenuated PSL-induced fibre derangement, swelling of nerve fibre and activation of neuroglial cells (satellite cells and Schwann cells) as markers of histopathological alteration.

Figures 4A and 4E show normal fibre arrangements. In Figures 4B and 4D, the black arrows show fibre derangement, swelling of nerve fibre and the presence of activated satellite cells and Schwann cells. In Figures 4C and 4E, attenuation of PSL-induced swelling of nerve fibres by trazodone (5 and 10 mg/kg) and standard treatment groups are observed, respectively.
FIGURE 4(A–E)- Effect of trazodone on partial sciatic nerve ligation-induced histopathological changes.
Effect of trazodone on biochemical parameters

PSL increased the oxidative stress markers and total calcium content as reflected when compared to the sham group. Treatment with trazodone (5mg and 10 mg/kg i.p.) significantly diminished the PSL-induced increase in oxidative stress markers (Figure 5A) and total calcium levels (Figure 5B).

FIGURE 5 - Effect of trazodone on oxidative stress markers and total calcium.

DISCUSSION

Neuropathic pain is a debilitating disease afflicting a wide population. Peripheral nerve injury produces a persistent neuropathic pain state characterised by spontaneous pain, allodynia and hyperalgesia (Obermann, 2019). In the present study, we assessed unilateral sciatic nerve ligation-induced behavioural and biochemical alterations in rats, and it was determined that unilateral ligation of the sciatic nerve in rats produced ipsilateral cold allodynia, thermal hyperalgesia, mechanical hyperalgesia and oxidative damage in the sciatic nerve (Gilron et al., 2006; Qin et al., 2019; Wallace et al., 2008).

In the present study, trazodone (5mg/kg and 10mg/kg) attenuated sciatic nerve ligation (i.e., PSL-induced behavioural [i.e., thermal and mechanical sensation], biochemical [i.e., lipid peroxidation and total calcium] and histopathological [i.e., axonal degeneration] changes). The behavioural alterations started on day 7 following the partial ligation of the sciatic nerve, followed by days 14 and 21.

During the present study, trazodone treatment significantly reversed thermal hyperalgesia, mechanical hyperalgesia and cold allodynia in sciatic nerve-ligated animals, thereby suggesting its therapeutic potential in the effective treatment and management of neuropathic pain. These findings suggest that trazodone plays an important role in pain regulation at the central and peripheral level. Moreover, it was observed that a low dose of trazodone has a less significant effect than a high dose.

In response to nerve injury, the initial steps of inflammatory reactions involve the release of pro-inflammatory mediators from the resident macrophages, Schwann cells and area adjacent to the nerve lesion. It has been documented that the sustained activation of peripheral nociceptors leads to the hypersensitivity of the primary afferent neurons and central sensitisation of the dorsal horn neurons (Brink et al., 2006).

Furthermore, PSL was associated with elevated oxidative stress, MDA levels and total calcium content in the present study. It has also been documented that oxidative stress and increased calcium levels play a critical role in neuropathic pain. However, treatment with trazodone attenuated the PSL-associated increase in oxidative stress and calcium levels. Trazodone administration exhibited an antioxidant effect...
and also decreased calcium levels. Notably, free radicals have been well documented to increase calcium levels. Therefore, the observed decrease in calcium levels with trazodone may possibly be attributed to its antioxidant effects (Brink et al., 2006; Gurpreet et al., 2010; Perez et al., 2004).

In the present study, PSL resulted in significant histopathological changes assessed in transverse sections of the sciatic nerve. In transverse sections, nerve derangement, axonal swelling and an increased number of Schwann and satellite cells were also noted. Administration of trazodone (5mg/kg and 10mg/kg) significantly attenuated PSL-induced fibre derangement, the swelling of nerve fibre and activation of neuroglial cells (satellite cells and Schwann cells) as markers of histopathological alterations.

**CONCLUSION**

The results of the present study suggest that the administration of anti-depressants results in antinociceptive activity in a PSL model of neuropathic pain. The current study exhibited the efficacy of trazodone in the prevention of neuropathic pain induced by PSL in rats. However, this study has some limitations. First, the sample sizes are relatively small. Second, there is variability in the selection of animals, and it is evident that there are variations in neuropathic pain that could potentially impact the results. In conclusion, trazodone may be used as an alternative to analgesics for the symptomatic treatment of neuropathic pain. Although the present evidence highlights the efficacy of trazodone, further research is required to expand on these findings. The present findings suggest that trazodone may be effective for preventing neuropathic pain, though future research can further elucidate the treatment of nociception in clinical practice.

**REFERENCES**


Brink CB, Harvey BH, and Brand L. Tianeptine - a novel atypical anti-depressant that may provide new insights into the biomolecular basis of depression. Recent Pat CNS Drug Discovery. 2006;1(1):29-41.


Alleviation of neuropathic pain by trazodone in rats


Received for publication on 21st March 2019
Accepted for publication on 16th May 2019